The data presented at SABCS further validates the best-in-class performance of Pathlight, SAGA’s structural-variant–based MRD ...

MADISON, Wis. - Exact Sciences Corp. (NASDAQ: EXAS), a leader in cancer screening and diagnostic tests with a market capitalization of $10 billion, announced clinical validation data for its ...

SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, will present five ...

BOSTON, September 23, 2025--(BUSINESS WIRE)--Foundation Medicine, Inc., a precision medicine company transforming lives in cancer care and beyond, today announced the addition of a tissue-informed ...

Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing ...

Personalis aims to lead the MRD liquid biopsy market with ultra-sensitive sequencing and upcoming Medicare coverage. Read here for more on PSNL stock.

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...

SEATTLE - Adaptive Biotechnologies (NASDAQ:ADPT) Corporation (NASDAQ:ADPT) announced today that its clonoSEQ assay has received expanded coverage from Palmetto GBA, a Medicare Administrative ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

Medicare beneficiaries with stage II and III breast cancer, including the three major subtypes HR+/HER2-, HER2+ and triple-negative breast cancer (TNBC), will now have coverage for recurrence ...

SEATTLE - Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a biotechnology company focused on understanding the adaptive immune system, announced that its clonoSEQ test for measurable residual ...